US6908506B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Magnesium ammonium phosphate cement composition
Assignee: Medtronic Europe SARL
•
Filing: 2004-02-04
•
Granted: 2005-06-21
•
Expires: 2024-02-04
Abstract
Abstract This invention relates to a cement, which comprises in its main phase of microcrystalline magnesium ammonium phosphate and nanoapatite after hardening and thus at the same time has considerable strength. The material is biologically degradable and is suitable for application in tooth cements, as bone replacement, as bone filler, as bone cement or as bone adhesive.
Inventors
- 👤 Michael Zimmermann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:10
CPC Classifications
C; C04; C04B; C04B28/00; C04B28/34; A; A61; A61K; A61K33/00; A61K33/06; A61K33/42; A61K45/00; A61K45/06; A61K6/00; A61K6/15; A61K6/17; A61K6/80; A61K6/831; A61K6/838; A61K6/849; A61K6/864; A61K6/867; A61L; A61L24/00; A61L24/001; A61L24/0036; A61L24/02; A61L27/00; A61L27/02; A61L27/12; A61L27/50; A61L27/56; A61P; A61P19/00; C04B28/344; C04B28/346; C04B28/348; A61B; A61B17/00; A61B17/00491; A61F; A61F2/00; A61F2/02; A61F2/28; A61F2/30; A61F2002/30001; A61F2002/30003; A61F2002/3006; A61F2002/30062; A61F2002/30316; A61F2002/30535; A61F2/46; A61F2002/4631; A61F2210/00; A61F2210/0004; A61F2250/00; A61F2250/0058; A61L2430/00; A61L2430/02; C04B2103/00; C04B2103/0004; C04B2103/0006; C04B2103/0009; C04B2111/00; C04B2111/00034; C04B2111/00206; C04B2111/00474; C04B2111/00836
Claims Analysis
Total Claims: 47
Claim 1
Independent Claim
36 words
A magnesium ammonium phosphate cement preparation comprising: a powder mixture having molar quantities of the components calcium (Ca), magnesium (Mg) and orthophosphate (P) in the mixture in the ranges 1<Ca/P<1.5 and Mg/P<0.5; and an ammonium salt.
Claim 2
Dependent Claim
36 words
A magnesium ammonium phosphate cement preparation comprising: a powder mixture having molar quantities of the components calcium (Ca), magnesium (Mg) and orthophosphate (P) in the mixture in the ranges 1<Ca/P<1.5 and Mg/P<0.5; and an ammonium salt.
Claim 3
Dependent Claim
25 words
The preparation according to claim 1 , wherein the ammonium salt comprises an aqueous solution having a pH in the range from 7 to 12.
Claim 4
Dependent Claim
28 words
The preparation according to claim 1 , wherein the ammonium salt is present in the powder mixture at molar quantity of ammonium (NH 4 ) less than 0.5.
Claim 5
Dependent Claim
16 words
The preparation according to claim 1 , wherein the powder mixture comprises α/β-tertiary calcium phosphate (α/β-TCP).
Claim 6
Dependent Claim
18 words
The preparation according to claim 4 , wherein the powder mixture further comprises MgHPO 4 .3H 2 O.
Claim 7
Dependent Claim
20 words
The preparation according to claim 5 , wherein the powder mixture further comprises Mg 3 (PO 4 ) 2 .
Claim 8
Dependent Claim
19 words
The preparation according to claim 1 , wherein the powder mixture comprises (NH 4 ) 2 SO 4 .
Claim 9
Dependent Claim
18 words
The preparation according to claim 1 , wherein the powder mixture further comprises KH 2 PO 4 .
Claim 10
Dependent Claim
18 words
The preparation according to claim 1 , wherein the powder mixture further comprises Na 2 HPO 4 .
Claim 11
Dependent Claim
12 words
The preparation according to claim 1 , further comprising SrCO 3 .
Claim 12
Dependent Claim
30 words
The preparation according to claim 10 , wherein the SrCO 3 is present in the range of 0.01 to 10 wt. % based on the total weight of the preparation.
Claim 13
Dependent Claim
30 words
The preparation according to claim 10 , wherein the SrCO 3 is present in the range of 0.1 to 5 wt. % based on the total weight of the preparation.
Claim 14
Dependent Claim
10 words
The preparation according to claim 1 , further comprising ZnO.
Claim 15
Dependent Claim
23 words
The preparation according to claim 1 , wherein the powder mixture further comprises Ca 2 NaK(PO 4 ) 2 and/or CaKPO 4 .
Claim 16
Dependent Claim
11 words
The preparation according to claim 1 , further comprising a fluoride.
Claim 17
Dependent Claim
16 words
The preparation according to claim 1 , further comprising a pharmaceutical and/or a bioactive active ingredient.
Claim 18
Dependent Claim
39 words
The preparation according to claim 16 , wherein the pharmaceutical and/or a bioactive active ingredient comprises a therapeutic dose of a component selected from the group consisting of antibiotics, cytostatic agents, analgesics, disinfectants, growth factors, proteins or elastin inhibitors.
Claim 19
Dependent Claim
30 words
A magnesium ammonium phosphate cement preparation comprising: a powder mixture comprising α-TCP, β-TCP, MgHPO4.3H 2 O, KH 2 PO 4 and Na 2 HPO 4 ; and an ammonium salt.
Claim 20
Dependent Claim
30 words
A magnesium ammonium phosphate cement preparation comprising: a powder mixture comprising α-TCP, β-TCP, MgHPO4.3H 2 O, KH 2 PO 4 and Na 2 HPO 4 ; and an ammonium salt.
Claim 21
Dependent Claim
16 words
The preparation according to claim 18 , wherein the powder mixture further comprises SrCO 3 .
Claim 22
Dependent Claim
30 words
The preparation according to claim 19 , wherein the SrCO 3 is present in a quantity of 0.01 to 10 wt. % based on the total weight of the preparation.
Claim 23
Dependent Claim
10 words
The preparation according to claim 18 , further comprising ZnO.
Claim 24
Dependent Claim
23 words
The preparation according to claim 18 , wherein the powder mixture further comprises Ca 2 NaK(PO 4 ) 2 and/or CaKPO 4 .
Claim 25
Dependent Claim
11 words
The preparation according to claim 18 , further comprising a fluoride.
Claim 26
Dependent Claim
16 words
The preparation according to claim 18 , further comprising a pharmaceutical and/or a bioactive active ingredient.
Claim 27
Dependent Claim
39 words
The preparation according to claim 24 , wherein the pharmaceutical and/or a bioactive active ingredient comprises a therapeutic dose of a component selected from the group consisting of antibiotics, cytostatic agents, analgesics, disinfectants, growth factors, proteins or elastin inhibitors.
Claim 28
Dependent Claim
34 words
A magnesium ammonium phosphate cement preparation comprising: a powder mixture comprising α-TCP, β-TCP, (NH 4 ) 2 SO 4 , KH 2 PO 4 and Na 2 HPO 4 ; and a magnesium salt.
Claim 29
Dependent Claim
34 words
A magnesium ammonium phosphate cement preparation comprising: a powder mixture comprising α-TCP, β-TCP, (NH 4 ) 2 SO 4 , KH 2 PO 4 and Na 2 HPO 4 ; and a magnesium salt.
Claim 30
Dependent Claim
17 words
The preparation according to claim 26 , wherein the magnesium salt is MgHPO 4 .3H 2 O.
Claim 31
Dependent Claim
16 words
The preparation according to claim 26 , wherein the powder mixture further comprises SrCO 3 .
Claim 32
Dependent Claim
27 words
The preparation according to claim 28 , wherein the SrCO 3 is present at 0.01 to 10 wt. % based on the total weight of the preparation.
Claim 33
Dependent Claim
10 words
The preparation according to claims 26 , further comprising ZnO.
Claim 34
Dependent Claim
23 words
The preparation according to claims 26 , wherein the powder mixture further comprises Ca 2 NaK(PO 4 ) 2 and/or CaKPO 4 .
Claim 35
Dependent Claim
11 words
The preparation according to claim 26 , further comprising a fluoride.
Claim 36
Dependent Claim
16 words
The preparation according to claim 26 , further comprising a pharmaceutical and/or a bioactive active ingredient.
Claim 37
Dependent Claim
39 words
The preparation according to claim 33 , wherein the pharmaceutical and/or a bioactive active ingredient comprises a therapeutic dose of a component selected from the group consisting of antibiotics, cytostatic agents, analgesics, disinfectants, growth factors, proteins or elastin inhibitors.
Claim 38
Dependent Claim
32 words
A magnesium ammonium phosphate cement preparation comprising: a powder mixture comprising α-TCP, β-TCP, primary or secondary ammonium phosphate, KH 2 PO 4 and Na 2 HPO 4 ; and a magnesium salt.
Claim 39
Dependent Claim
32 words
A magnesium ammonium phosphate cement preparation comprising: a powder mixture comprising α-TCP, β-TCP, primary or secondary ammonium phosphate, KH 2 PO 4 and Na 2 HPO 4 ; and a magnesium salt.
Claim 40
Dependent Claim
17 words
The preparation according to claim 35 , wherein the magnesium salt is MgHPO 4 .3H 2 O.
Claim 41
Dependent Claim
16 words
The preparation according to claim 35 , wherein the powder mixture further comprises SrCO 3 .
Claim 42
Dependent Claim
27 words
The preparation according to claim 37 , wherein the SrCO 3 is present at 0.01 to 10 wt. % based on the total weight of the preparation.
Claim 43
Dependent Claim
10 words
The preparation according to claim 35 , further comprising ZnO.
Claim 44
Dependent Claim
23 words
The preparation according to claim 35 , wherein the powder mixture further comprises Ca 2 NaK(PO 4 ) 2 and/or CaKPO 4 .
Claim 45
Dependent Claim
11 words
The preparation according to claim 35 , further comprising a fluoride.
Claim 46
Dependent Claim
16 words
The preparation according to claim 35 , further comprising a pharmaceutical and/or a bioactive active ingredient.
Claim 47
Dependent Claim
39 words
The preparation according to claim 42 , wherein the pharmaceutical and/or a bioactive active ingredient comprises a therapeutic dose of a component selected from the group consisting of antibiotics, cytostatic agents, analgesics, disinfectants, growth factors, proteins or elastin inhibitors.
References Cited (Backward Citations)
US4518430A
Cited
US4612053A
Cited
US4959104A
Cited
US5952010A
Cited
US5149368A
Cited
WO1995013835A1
Cited
US5262166A
Cited
US5605713A
Cited
EP0543765A1
Cited
US5281265A
Cited
EP0835668A1
Cited
WO1996014265A1
Cited
US6692563B2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2008-06-20 | 2008-12-20 | 2009-06-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2012-06-20 | 2012-12-20 | 2013-06-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2016-06-20 | 2016-12-20 | 2017-06-21 | $7700.00 | Window Closed / Lapsed |